Research programme: therapeutic drug formulations - Imprimis Pharmaceuticals

Drug Profile

Research programme: therapeutic drug formulations - Imprimis Pharmaceuticals

Alternative Names: Bacitracin/tranexamic-acid; IPI-120; Tranexamic acid/bacitracin; Wound management therapeutics - Imprimis

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Buderer Drug Co
  • Developer Imprimis Pharmaceuticals
  • Class Cyclic peptides; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wound infections; Wounds
  • Research Dental caries
  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
  • 25 Nov 2013 Preclinical trials in Wound infections in USA (Transdermal)
  • 25 Nov 2013 Preclinical trials in Wounds in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top